Bioethics Blogs

Research Ethics Roundup: New Setback for Marijuana Research, Genetic Testing Companies’ Security Concerns, Chimera Research and Review Boards, and the European Medicines Agency’s Attempt to Decrease Risks in “First-In-Human” Studies

This week’s Research Ethics Roundup highlights the research implications of the Drug Enforcement Administration (DEA) decision to keep marijuana a Schedule 1 drug, public concern about hackers and stored genetic information, one bioethics professor’s take on the National Institutes of Health’s proposed policy for funding chimera research, and the European Medicines Agency’s response to a French clinical trial that left one man dead.

The post Research Ethics Roundup: New Setback for Marijuana Research, Genetic Testing Companies’ Security Concerns, Chimera Research and Review Boards, and the European Medicines Agency’s Attempt to Decrease Risks in “First-In-Human” Studies appeared first on Ampersand.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.